Enstilar adjunct therapy

Placeholder for clinical news, RWE and papers on Enstilar concomitant usage with other actives and/or as an adjunct therapy with biologics / systemics

Would you like to connect with LEO Pharma?


Register to access to the latest developments, data, resources and offerings from LEO Pharma


Email your questions or requests directly to LEO Pharma.


1.Koo J, et al. J Dermatolog Treat 2016;27(2):120-127.

2.Enstilar® Australian Product Information 22-March-2022


4.Data on File: LEO90100 – 003 MAR 2016

5.Paul C, Stein Gold L, Cambazard F et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2017;31;119-26.

6.Warren R et al. Poster 10348 presented at the 74th AAD Conference; Washington DC, USA, 4–8 March 2016.

7.Savary J et al. JEADV 2005; 19(Suppl. 3): 14-17

LEO Pharma Pty Ltd, ABN 72 147 880 617, Brisbane, QLD 4005. Enstilar®, Daivobet®  LEO and LEO/lion device are registered trademarks of LEO Pharma A/S. ©Copyright 2022. Prepared April 2022. MAT-55769